{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "07be992e",
   "metadata": {},
   "source": [
    "precision Í≥ÑÏÇ∞"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f1bdb8f1",
   "metadata": {},
   "source": [
    "Îß§Ïπ≠Îê† title Ï†ÑÏ≤òÎ¶¨"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "e5650d86",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== Ï†ïÎãµÏÖã Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\n",
      "0    conditionally reprogrammed colorectal cancer c...\n",
      "1    combining mek and src inhibitors for treatment...\n",
      "2    sensitivity of kras mutant colorectal cancers ...\n",
      "3    targeting ras mutant colorectal cancer with du...\n",
      "4    mcl 1 inhibition overcomes intrinsic and acqui...\n",
      "Name: title, dtype: object\n",
      "\n",
      "=== ÏòàÏ∏°ÏÖã Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\n",
      "0    wee1 confers resistance to krasg12c inhibitors...\n",
      "1    palbociclib overcomes afatinib resistance in n...\n",
      "2    regorafenib suppresses epidermal growth factor...\n",
      "3    her2 exon 20 insertions in non small cell lung...\n",
      "4    xie bai san increases nsclc cells sensitivity ...\n",
      "Name: title, dtype: object\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "t0 = pd.read_csv(\"t000.csv\", encoding='cp949') # Ï†ïÎãµÏÖã title,drugÎßå ÏûàÎäî Í±∞\n",
    "t1 = pd.read_csv(\"t4.csv\", encoding='utf-8') # Í∑∏ÎïåÍ∑∏Îïå Ï∂îÏ∂úÌïú Ï∂îÏ∂úÏÖã \n",
    "\n",
    "# 1Ô∏è‚É£ title Ï†ÑÏ≤òÎ¶¨ Ìï®Ïàò\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # ÏÜåÎ¨∏Ïûê ÌÜµÏùº\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # ÌäπÏàòÎ¨∏Ïûê Ï†úÍ±∞\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # Í≥µÎ∞± ÌÜµÏùº\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "# 2Ô∏è‚É£ t0, t1Ïùò title Ïª¨Îüº Ï†ÑÏ≤òÎ¶¨\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 3Ô∏è‚É£ Ï†ÑÏ≤òÎ¶¨ ÌôïÏù∏ (ÏÉÅÏúÑ 5Í∞ú)\n",
    "print(\"=== Ï†ïÎãµÏÖã Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\")\n",
    "print(t0[\"title\"].head())\n",
    "print(\"\\n=== ÏòàÏ∏°ÏÖã Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\")\n",
    "print(t1[\"title\"].head())\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e34191fb",
   "metadata": {},
   "source": [
    "ÏûêÏπ¥Ìä∏Î•¥ Ïú†ÏÇ¨ÎèÑ title Îß§Ïπ≠: Í∏∞Ï§Ä .7"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "8dd7c8d0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Îß§Ïπ≠Îêú title Í∞úÏàò: 33\n",
      "\n",
      "=== Title Ïú†ÏÇ¨ÎèÑ Îß§Ïπ≠ Í≤∞Í≥º (ÏÉÅÏúÑ 10Í∞ú) ===\n",
      "                                             title_t0  \\\n",
      "0   sensitivity of kras mutant colorectal cancers ...   \n",
      "1   phase ib study of vemurafenib in combination w...   \n",
      "2   regorafenib suppresses epidermal growth factor...   \n",
      "3   regorafenib inhibits colorectal tumor growth t...   \n",
      "4   targeting methionine addiction combined with l...   \n",
      "5   combining neratinib with cdk4 6 mtor and mek i...   \n",
      "6   expression of mt4 mmp egfr and rb in triple ne...   \n",
      "7   doublet and triplet combinations of eribulin f...   \n",
      "8   carbon nanotube capsules enhance the in vivo e...   \n",
      "9   dual mtor kinase inhibitor mln0128 sensitizes ...   \n",
      "10  acquired resistance to endocrine treatments is...   \n",
      "11  3 dimensional patient derived lung cancer assa...   \n",
      "12  preclinical antitumor efficacy of bay 1129980 ...   \n",
      "13  the fact inhibitor cbl0137 synergizes with cis...   \n",
      "14  patient derived non small cell lung cancer xen...   \n",
      "15  differential antitumor activity of aflibercept...   \n",
      "16  discontinuous schedule of bevacizumab in color...   \n",
      "17  preclinical evaluation and phase ib study of p...   \n",
      "18  pharmacological targeting of androgen receptor...   \n",
      "19  acquired resistance to endocrine treatments is...   \n",
      "20  preclinical activity of her2 selective tyrosin...   \n",
      "21  combination therapy with mdm2 and mek inhibito...   \n",
      "22  palbociclib overcomes afatinib resistance in n...   \n",
      "23  her2 exon 20 insertions in non small cell lung...   \n",
      "24  novel preclinical patient derived lung cancer ...   \n",
      "25  rapid acquisition of alectinib resistance in a...   \n",
      "26  ono 7475 a novel axl inhibitor suppresses the ...   \n",
      "27  enhancing the therapeutic efficacy of gefitini...   \n",
      "28  xie bai san increases nsclc cells sensitivity ...   \n",
      "29  pharmacokinetic pharmacodynamic analysis of sa...   \n",
      "30  diverse resistance mechanisms to the third gen...   \n",
      "31  wee1 confers resistance to krasg12c?inhibitors...   \n",
      "32  antitumor efficacy of xpo1 inhibitor selinexor...   \n",
      "\n",
      "                                             title_t1  similarity  \n",
      "0   sensitivity of kras mutant colorectal cancers ...    1.000000  \n",
      "1   phase ib study of vemurafenib in combination w...    1.000000  \n",
      "2   regorafenib suppresses epidermal growth factor...    1.000000  \n",
      "3   regorafenib inhibits colorectal tumor growth t...    1.000000  \n",
      "4   targeting methionine addiction combined with l...    1.000000  \n",
      "5   combining neratinib with cdk4 6 mtor and mek i...    1.000000  \n",
      "6   expression of mt4 mmp egfr and rb in triple ne...    1.000000  \n",
      "7   doublet and triplet combinations of eribulin f...    1.000000  \n",
      "8   carbon nanotube capsules enhance the in vivo e...    1.000000  \n",
      "9   dual mtor kinase inhibitor mln0128 sensitizes ...    1.000000  \n",
      "10  acquired resistance to endocrine treatments is...    1.000000  \n",
      "11  3 dimensional patient derived lung cancer assa...    1.000000  \n",
      "12  preclinical antitumor efficacy of bay 1129980 ...    1.000000  \n",
      "13  the fact inhibitor cbl0137 synergizes with cis...    1.000000  \n",
      "14  patient derived non small cell lung cancer xen...    1.000000  \n",
      "15  differential antitumor activity of aflibercept...    1.000000  \n",
      "16  discontinuous schedule of bevacizumab in color...    1.000000  \n",
      "17  preclinical evaluation and phase ib study of p...    1.000000  \n",
      "18  pharmacological targeting of androgen receptor...    1.000000  \n",
      "19  acquired resistance to endocrine treatments is...    1.000000  \n",
      "20  preclinical activity of her2 selective tyrosin...    1.000000  \n",
      "21  combination therapy with mdm2 and mek inhibito...    1.000000  \n",
      "22  palbociclib overcomes afatinib resistance in n...    1.000000  \n",
      "23  her2 exon 20 insertions in non small cell lung...    1.000000  \n",
      "24  novel preclinical patient derived lung cancer ...    1.000000  \n",
      "25  rapid acquisition of alectinib resistance in a...    1.000000  \n",
      "26  ono 7475 a novel axl inhibitor suppresses the ...    1.000000  \n",
      "27  enhancing the therapeutic efficacy of gefitini...    1.000000  \n",
      "28  xie bai san increases nsclc cells sensitivity ...    1.000000  \n",
      "29  pharmacokinetic pharmacodynamic analysis of sa...    1.000000  \n",
      "30  diverse resistance mechanisms to the third gen...    1.000000  \n",
      "31  wee1 confers resistance to krasg12c inhibitors...    0.769231  \n",
      "32  antitumor efficacy of xpo1 inhibitor selinexor...    1.000000  \n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1Ô∏è‚É£ title Ï†ÑÏ≤òÎ¶¨\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # ÏÜåÎ¨∏Ïûê ÌÜµÏùº\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # ÌäπÏàòÎ¨∏Ïûê Ï†úÍ±∞\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # Í≥µÎ∞± ÌÜµÏùº\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 2Ô∏è‚É£ Jaccard Ïú†ÏÇ¨ÎèÑ Ìï®Ïàò\n",
    "def jaccard_similarity(str1, str2):\n",
    "    set1 = set(str1.split())\n",
    "    set2 = set(str2.split())\n",
    "    if not set1 or not set2:\n",
    "        return 0\n",
    "    return len(set1 & set2) / len(set1 | set2)\n",
    "\n",
    "threshold = 0.7  # Ïú†ÏÇ¨ÎèÑ Í∏∞Ï§Ä (Ï°∞Ï†ï Í∞ÄÎä•)\n",
    "\n",
    "# 3Ô∏è‚É£ title Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠\n",
    "matches = []\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "\n",
    "# 4Ô∏è‚É£ Í≤∞Í≥º ÌôïÏù∏\n",
    "print(f\"Îß§Ïπ≠Îêú title Í∞úÏàò: {matched_df.shape[0]}\")\n",
    "print(\"\\n=== Title Ïú†ÏÇ¨ÎèÑ Îß§Ïπ≠ Í≤∞Í≥º (ÏÉÅÏúÑ 10Í∞ú) ===\")\n",
    "# print(matched_df.head(10))\n",
    "print(matched_df)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ab934431",
   "metadata": {},
   "source": [
    "ÎìúÎü¨Í∑∏ Ï†ÑÏ≤òÎ¶¨"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "1ebe8c33",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Îß§Ïπ≠Îêú title Í∞úÏàò: 33\n",
      "\n",
      "=== Drug Precision ===\n",
      "üîπ Macro Precision (ÌñâÎ≥Ñ ÌèâÍ∑†): 0.4899\n",
      "üîπ Micro Precision (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): 0.6087\n",
      "------------------------------------\n",
      "Title T0: sensitivity of kras mutant colorectal cancers to combination therapy that cotargets mek and cdk4 6\n",
      "Title T1: sensitivity of kras mutant colorectal cancers to combination therapy that cotargets mek and cdk4 6\n",
      "Drug T0: ['palbociclib', 'trametinib']\n",
      "Drug T1: ['trametinib']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation\n",
      "Title T1: phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation\n",
      "Drug T0: ['irinotecan', 'vemurafenib', 'cetuximab']\n",
      "Drug T1: ['irinotecanirinotecan']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: regorafenib suppresses epidermal growth factor receptor signaling modulated progression of colorectal cancer\n",
      "Title T1: regorafenib suppresses epidermal growth factor receptor signaling modulated progression of colorectal cancer\n",
      "Drug T0: ['regorafenib']\n",
      "Drug T1: ['regorafenib', 'erlotinib', '6bromo(2chlorophenyl)quinazoline2one']\n",
      "Precision (row): 0.3333333333333333\n",
      "------------------------------------\n",
      "Title T0: regorafenib inhibits colorectal tumor growth through puma mediated apoptosis\n",
      "Title T1: regorafenib inhibits colorectal tumor growth through puma mediated apoptosis\n",
      "Drug T0: ['regorafenib']\n",
      "Drug T1: ['regorafenib']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: targeting methionine addiction combined with low dose irinotecan arrested colon cancer in contrast to high dose irinotecan alone which was ineffective in a nude mouse model\n",
      "Title T1: targeting methionine addiction combined with low dose irinotecan arrested colon cancer in contrast to high dose irinotecan alone which was ineffective in a nude mouse model\n",
      "Drug T0: ['irinotecan']\n",
      "Drug T1: ['irinotecan']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: combining neratinib with cdk4 6 mtor and mek inhibitors in models of her2 positive cancer\n",
      "Title T1: combining neratinib with cdk4 6 mtor and mek inhibitors in models of her2 positive cancer\n",
      "Drug T0: ['everolimus', 'neratinib', 'palbociclib', 'trametinib']\n",
      "Drug T1: ['everolimus']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: expression of mt4 mmp egfr and rb in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy\n",
      "Title T1: expression of mt4 mmp egfr and rb in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy\n",
      "Drug T0: ['erlotinib', 'palbociclib']\n",
      "Drug T1: ['palbociclib']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: doublet and triplet combinations of eribulin fulvestrant and palbociclib in preclinical breast cancer models\n",
      "Title T1: doublet and triplet combinations of eribulin fulvestrant and palbociclib in preclinical breast cancer models\n",
      "Drug T0: ['eribulin', 'fulvestrant', 'palbociclib']\n",
      "Drug T1: ['eribulin']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: carbon nanotube capsules enhance the in vivo efficacy of cisplatin\n",
      "Title T1: carbon nanotube capsules enhance the in vivo efficacy of cisplatin\n",
      "Drug T0: ['cisplatin']\n",
      "Drug T1: ['bevacizumab']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: dual mtor kinase inhibitor mln0128 sensitizes hr+ her2+ breast cancer patient derived xenografts to trastuzumab or fulvestrant\n",
      "Title T1: dual mtor kinase inhibitor mln0128 sensitizes hr+ her2+ breast cancer patient derived xenografts to trastuzumab or fulvestrant\n",
      "Drug T0: ['trastuzumab']\n",
      "Drug T1: ['fulvestrant']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Title T1: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Drug T0: ['everolimus']\n",
      "Drug T1: ['everolimus']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: 3 dimensional patient derived lung cancer assays reveal resistance to standards of care promoted by stromal cells but sensitivity to histone deacetylase inhibitors\n",
      "Title T1: 3 dimensional patient derived lung cancer assays reveal resistance to standards of care promoted by stromal cells but sensitivity to histone deacetylase inhibitors\n",
      "Drug T0: ['carboplatin', 'paclitaxel']\n",
      "Drug T1: ['quisinostat']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: preclinical antitumor efficacy of bay 1129980 a novel auristatin based anti c4.4a lypd3 antibody drug conjugate for the treatment of non small cell lung cancer\n",
      "Title T1: preclinical antitumor efficacy of bay 1129980 a novel auristatin based anti c4.4a lypd3 antibody drug conjugate for the treatment of non small cell lung cancer\n",
      "Drug T0: ['carboplatin', 'cisplatin', 'docetaxel']\n",
      "Drug T1: ['bay1129980']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: the fact inhibitor cbl0137 synergizes with cisplatin in small cell lung cancer by increasing?notch1?expression and targeting tumor initiating cells\n",
      "Title T1: the fact inhibitor cbl0137 synergizes with cisplatin in small cell lung cancer by increasing?notch1?expression and targeting tumor initiating cells\n",
      "Drug T0: ['cbl1037', 'cisplatin']\n",
      "Drug T1: ['cbl0137']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: patient derived non small cell lung cancer xenograft mirrors complex tumor heterogeneity\n",
      "Title T1: patient derived non small cell lung cancer xenograft mirrors complex tumor heterogeneity\n",
      "Drug T0: ['atezolizumab', 'cisplatin']\n",
      "Drug T1: ['paclitaxel']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: differential antitumor activity of aflibercept and bevacizumab in patient derived xenograft models of colorectal cancer\n",
      "Title T1: differential antitumor activity of aflibercept and bevacizumab in patient derived xenograft models of colorectal cancer\n",
      "Drug T0: ['bevacizumab']\n",
      "Drug T1: ['bevacizumab']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes\n",
      "Title T1: discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes\n",
      "Drug T0: ['bevacizumab']\n",
      "Drug T1: ['topotecan']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: preclinical evaluation and phase ib study of prexasertib a chk1 inhibitor and samotolisib ly3023414 a dual pi3k mtor inhibitor\n",
      "Title T1: preclinical evaluation and phase ib study of prexasertib a chk1 inhibitor and samotolisib ly3023414 a dual pi3k mtor inhibitor\n",
      "Drug T0: ['prexasertib', 'samotolisib']\n",
      "Drug T1: ['ibrutinib']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: pharmacological targeting of androgen receptor elicits context specific effects in estrogen receptor positive breast cancer\n",
      "Title T1: pharmacological targeting of androgen receptor elicits context specific effects in estrogen receptor positive breast cancer\n",
      "Drug T0: ['fulvestrant']\n",
      "Drug T1: ['enzalutamide']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Title T1: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Drug T0: ['everolimus', 'fulvestrant', 'letrozole', 'ovariectomy', 'tamoxifen']\n",
      "Drug T1: ['everolimus']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: preclinical activity of her2 selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models\n",
      "Title T1: preclinical activity of her2 selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models\n",
      "Drug T0: ['docetaxel', 'trastuzumab', 'tucatinib']\n",
      "Drug T1: ['tucatinib']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: combination therapy with mdm2 and mek inhibitors is effective in patient derived models of lung adenocarcinoma with concurrent oncogenic drivers and mdm2 amplification\n",
      "Title T1: combination therapy with mdm2 and mek inhibitors is effective in patient derived models of lung adenocarcinoma with concurrent oncogenic drivers and mdm2 amplification\n",
      "Drug T0: ['milademetan', 'trametinib']\n",
      "Drug T1: ['trametinib', 'milademetan', 'selpercatinib']\n",
      "Precision (row): 0.6666666666666666\n",
      "------------------------------------\n",
      "Title T0: palbociclib overcomes afatinib resistance in non small cell lung cancer\n",
      "Title T1: palbociclib overcomes afatinib resistance in non small cell lung cancer\n",
      "Drug T0: ['afatinib', 'palbociclib']\n",
      "Drug T1: ['palbociclib', 'letrozole', 'afatinib']\n",
      "Precision (row): 0.6666666666666666\n",
      "------------------------------------\n",
      "Title T0: her2 exon 20 insertions in non small cell lung cancer are sensitive to the irreversible pan her receptor tyrosine kinase inhibitor pyrotinib\n",
      "Title T1: her2 exon 20 insertions in non small cell lung cancer are sensitive to the irreversible pan her receptor tyrosine kinase inhibitor pyrotinib\n",
      "Drug T0: ['afatinib']\n",
      "Drug T1: ['pyrotinib', 'afatinib', 'trastuzumabemtansine']\n",
      "Precision (row): 0.3333333333333333\n",
      "------------------------------------\n",
      "Title T0: novel preclinical patient derived lung cancer models reveal inhibition of her3 and mtor signaling as therapeutic strategies for nrg1 fusion positive cancers\n",
      "Title T1: novel preclinical patient derived lung cancer models reveal inhibition of her3 and mtor signaling as therapeutic strategies for nrg1 fusion positive cancers\n",
      "Drug T0: ['afatinib']\n",
      "Drug T1: ['sirolimus', 'dnp53']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: rapid acquisition of alectinib resistance in alk positive lung cancer with high tumor mutation burden\n",
      "Title T1: rapid acquisition of alectinib resistance in alk positive lung cancer with high tumor mutation burden\n",
      "Drug T0: ['alectinib', 'crizotinib', 'erlotinib', 'lorlatinib']\n",
      "Drug T1: ['alectinib', 'lorlatinib']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: ono 7475 a novel axl inhibitor suppresses the adaptive resistance to initial egfr tki treatment in egfr mutated non small cell lung cancer\n",
      "Title T1: ono 7475 a novel axl inhibitor suppresses the adaptive resistance to initial egfr tki treatment in egfr mutated non small cell lung cancer\n",
      "Drug T0: ['osimertinib']\n",
      "Drug T1: ['tamnorzatinib']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: enhancing the therapeutic efficacy of gefitinib in human non small cell lung cancer through drug combination\n",
      "Title T1: enhancing the therapeutic efficacy of gefitinib in human non small cell lung cancer through drug combination\n",
      "Drug T0: ['dbdx', 'gefitinib']\n",
      "Drug T1: ['iodogen']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: xie bai san increases nsclc cells sensitivity to gefitinib by inhibiting beclin 1 mediated autophagosome formation\n",
      "Title T1: xie bai san increases nsclc cells sensitivity to gefitinib by inhibiting beclin 1 mediated autophagosome formation\n",
      "Drug T0: ['gefitinib', 'xbs']\n",
      "Drug T1: ['sirolimus', 'gefitinib']\n",
      "Precision (row): 0.5\n",
      "------------------------------------\n",
      "Title T0: pharmacokinetic pharmacodynamic analysis of savolitinib plus osimertinib in an egfr mutation positive met amplified non small cell lung cancer model\n",
      "Title T1: pharmacokinetic pharmacodynamic analysis of savolitinib plus osimertinib in an egfr mutation positive met amplified non small cell lung cancer model\n",
      "Drug T0: ['osimertinib']\n",
      "Drug T1: ['osimertinib']\n",
      "Precision (row): 1.0\n",
      "------------------------------------\n",
      "Title T0: diverse resistance mechanisms to the third generation alk inhibitor lorlatinib in alk rearranged lung cancer\n",
      "Title T1: diverse resistance mechanisms to the third generation alk inhibitor lorlatinib in alk rearranged lung cancer\n",
      "Drug T0: ['lorlatinib']\n",
      "Drug T1: ['vistusertib']\n",
      "Precision (row): 0.0\n",
      "------------------------------------\n",
      "Title T0: wee1 confers resistance to krasg12c?inhibitors in non small cell lung cancer\n",
      "Title T1: wee1 confers resistance to krasg12c inhibitors in non small cell lung cancer\n",
      "Drug T0: ['adavosertib', 'sotorasib']\n",
      "Drug T1: ['sotorasib', 'adavosertib', 'puromycin']\n",
      "Precision (row): 0.6666666666666666\n",
      "------------------------------------\n",
      "Title T0: antitumor efficacy of xpo1 inhibitor selinexor in?kras mutant lung adenocarcinoma patient derived xenografts\n",
      "Title T1: antitumor efficacy of xpo1 inhibitor selinexor in?kras mutant lung adenocarcinoma patient derived xenografts\n",
      "Drug T0: ['crizotinib', 'erlotinib', 'selinexor', 'trametinib']\n",
      "Drug T1: ['selinexor']\n",
      "Precision (row): 1.0\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "# t0 = pd.read_csv(\"t0.csv\", encoding='cp949')\n",
    "# t1 = pd.read_csv(\"t1.csv\", encoding='utf-8')\n",
    "\n",
    "# 1Ô∏è‚É£ Title Ï†ÑÏ≤òÎ¶¨ Ìï®Ïàò\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)\n",
    "    title = re.sub(r\"\\s+\", \" \", title)\n",
    "    return title.strip()\n",
    "\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 2Ô∏è‚É£ Jaccard Ïú†ÏÇ¨ÎèÑ Ìï®Ïàò\n",
    "def jaccard_similarity(str1, str2):\n",
    "    set1 = set(str1.split())\n",
    "    set2 = set(str2.split())\n",
    "    if not set1 or not set2:\n",
    "        return 0\n",
    "    return len(set1 & set2) / len(set1 | set2)\n",
    "\n",
    "threshold = 0.7  # Ïú†ÏÇ¨ÎèÑ Í∏∞Ï§Ä\n",
    "\n",
    "# 3Ô∏è‚É£ Title Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠\n",
    "matches = []\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim,\n",
    "                \"drug_t0\": row0[\"drug\"],\n",
    "                \"drug_t1\": row1[\"drug\"]\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "print(f\"Îß§Ïπ≠Îêú title Í∞úÏàò: {matched_df.shape[0]}\")\n",
    "\n",
    "# 4Ô∏è‚É£ Drug Ï†ÑÏ≤òÎ¶¨\n",
    "def preprocess_drug(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\") if d.strip()]\n",
    "\n",
    "matched_df[\"drug_t0_list\"] = matched_df[\"drug_t0\"].apply(preprocess_drug)\n",
    "matched_df[\"drug_t1_list\"] = matched_df[\"drug_t1\"].apply(preprocess_drug)\n",
    "\n",
    "# 5Ô∏è‚É£ Precision Í≥ÑÏÇ∞: pred(t1) Í∏∞Ï§Ä\n",
    "def compute_precision(row):\n",
    "    set_pred = set(row[\"drug_t1_list\"])\n",
    "    set_true = set(row[\"drug_t0_list\"])\n",
    "    if len(set_pred) == 0:\n",
    "        return 0\n",
    "    return len(set_pred & set_true) / len(set_pred)\n",
    "\n",
    "matched_df[\"row_precision\"] = matched_df.apply(compute_precision, axis=1)\n",
    "precision_macro = matched_df[\"row_precision\"].mean()  # ÌñâÎ≥Ñ ÌèâÍ∑† Precision\n",
    "precision_micro = matched_df[\"drug_t1_list\"].explode().isin(\n",
    "    matched_df[\"drug_t0_list\"].explode()\n",
    ").sum() / matched_df[\"drug_t1_list\"].explode().shape[0]  # Ï†ÑÏ≤¥ Í∏∞Ï§Ä Precision\n",
    "\n",
    "# 6Ô∏è‚É£ Í≤∞Í≥º Ï∂úÎ†•\n",
    "print(\"\\n=== Drug Precision ===\")\n",
    "print(f\"üîπ Macro Precision (ÌñâÎ≥Ñ ÌèâÍ∑†): {precision_macro:.4f}\")\n",
    "print(f\"üîπ Micro Precision (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): {precision_micro:.4f}\")\n",
    "\n",
    "# 7Ô∏è‚É£ ÌñâÎ≥Ñ ÏÉÅÏÑ∏ Ï∂úÎ†• (ÏòµÏÖò)\n",
    "for idx, row in matched_df.iterrows():\n",
    "    print(\"------------------------------------\")\n",
    "    print(f\"Title T0: {row['title_t0']}\")\n",
    "    print(f\"Title T1: {row['title_t1']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0_list']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1_list']}\")\n",
    "    print(f\"Precision (row): {row['row_precision']}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c272ecf5",
   "metadata": {},
   "source": [
    "recall, f1 Ìï®Íªò Í≥ÑÏÇ∞"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "5c4465fe",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=== Drug Precision & Recall & F1 ===\n",
      "üîπ Macro Precision (ÌñâÎ≥Ñ ÌèâÍ∑†): 0.4899\n",
      "üîπ Micro Precision (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): 0.6087\n",
      "üîπ Macro Recall (ÌñâÎ≥Ñ ÌèâÍ∑†): 0.4051\n",
      "üîπ Micro Recall (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): 0.4308\n",
      "üîπ Macro F1 (ÌñâÎ≥Ñ ÌèâÍ∑†): 0.3949\n",
      "üîπ Micro F1 (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): 0.5045\n",
      "------------------------------------\n",
      "Title T0: sensitivity of kras mutant colorectal cancers to combination therapy that cotargets mek and cdk4 6\n",
      "Title T1: sensitivity of kras mutant colorectal cancers to combination therapy that cotargets mek and cdk4 6\n",
      "Drug T0: ['palbociclib', 'trametinib']\n",
      "Drug T1: ['trametinib']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.5000\n",
      "F1 (row): 0.6667\n",
      "------------------------------------\n",
      "Title T0: phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation\n",
      "Title T1: phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation\n",
      "Drug T0: ['irinotecan', 'vemurafenib', 'cetuximab']\n",
      "Drug T1: ['irinotecanirinotecan']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: regorafenib suppresses epidermal growth factor receptor signaling modulated progression of colorectal cancer\n",
      "Title T1: regorafenib suppresses epidermal growth factor receptor signaling modulated progression of colorectal cancer\n",
      "Drug T0: ['regorafenib']\n",
      "Drug T1: ['regorafenib', 'erlotinib', '6bromo(2chlorophenyl)quinazoline2one']\n",
      "Precision (row): 0.3333\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 0.5000\n",
      "------------------------------------\n",
      "Title T0: regorafenib inhibits colorectal tumor growth through puma mediated apoptosis\n",
      "Title T1: regorafenib inhibits colorectal tumor growth through puma mediated apoptosis\n",
      "Drug T0: ['regorafenib']\n",
      "Drug T1: ['regorafenib']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 1.0000\n",
      "------------------------------------\n",
      "Title T0: targeting methionine addiction combined with low dose irinotecan arrested colon cancer in contrast to high dose irinotecan alone which was ineffective in a nude mouse model\n",
      "Title T1: targeting methionine addiction combined with low dose irinotecan arrested colon cancer in contrast to high dose irinotecan alone which was ineffective in a nude mouse model\n",
      "Drug T0: ['irinotecan']\n",
      "Drug T1: ['irinotecan']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 1.0000\n",
      "------------------------------------\n",
      "Title T0: combining neratinib with cdk4 6 mtor and mek inhibitors in models of her2 positive cancer\n",
      "Title T1: combining neratinib with cdk4 6 mtor and mek inhibitors in models of her2 positive cancer\n",
      "Drug T0: ['everolimus', 'neratinib', 'palbociclib', 'trametinib']\n",
      "Drug T1: ['everolimus']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.2500\n",
      "F1 (row): 0.4000\n",
      "------------------------------------\n",
      "Title T0: expression of mt4 mmp egfr and rb in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy\n",
      "Title T1: expression of mt4 mmp egfr and rb in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy\n",
      "Drug T0: ['erlotinib', 'palbociclib']\n",
      "Drug T1: ['palbociclib']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.5000\n",
      "F1 (row): 0.6667\n",
      "------------------------------------\n",
      "Title T0: doublet and triplet combinations of eribulin fulvestrant and palbociclib in preclinical breast cancer models\n",
      "Title T1: doublet and triplet combinations of eribulin fulvestrant and palbociclib in preclinical breast cancer models\n",
      "Drug T0: ['eribulin', 'fulvestrant', 'palbociclib']\n",
      "Drug T1: ['eribulin']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.3333\n",
      "F1 (row): 0.5000\n",
      "------------------------------------\n",
      "Title T0: carbon nanotube capsules enhance the in vivo efficacy of cisplatin\n",
      "Title T1: carbon nanotube capsules enhance the in vivo efficacy of cisplatin\n",
      "Drug T0: ['cisplatin']\n",
      "Drug T1: ['bevacizumab']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: dual mtor kinase inhibitor mln0128 sensitizes hr+ her2+ breast cancer patient derived xenografts to trastuzumab or fulvestrant\n",
      "Title T1: dual mtor kinase inhibitor mln0128 sensitizes hr+ her2+ breast cancer patient derived xenografts to trastuzumab or fulvestrant\n",
      "Drug T0: ['trastuzumab']\n",
      "Drug T1: ['fulvestrant']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Title T1: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Drug T0: ['everolimus']\n",
      "Drug T1: ['everolimus']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 1.0000\n",
      "------------------------------------\n",
      "Title T0: 3 dimensional patient derived lung cancer assays reveal resistance to standards of care promoted by stromal cells but sensitivity to histone deacetylase inhibitors\n",
      "Title T1: 3 dimensional patient derived lung cancer assays reveal resistance to standards of care promoted by stromal cells but sensitivity to histone deacetylase inhibitors\n",
      "Drug T0: ['carboplatin', 'paclitaxel']\n",
      "Drug T1: ['quisinostat']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: preclinical antitumor efficacy of bay 1129980 a novel auristatin based anti c4.4a lypd3 antibody drug conjugate for the treatment of non small cell lung cancer\n",
      "Title T1: preclinical antitumor efficacy of bay 1129980 a novel auristatin based anti c4.4a lypd3 antibody drug conjugate for the treatment of non small cell lung cancer\n",
      "Drug T0: ['carboplatin', 'cisplatin', 'docetaxel']\n",
      "Drug T1: ['bay1129980']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: the fact inhibitor cbl0137 synergizes with cisplatin in small cell lung cancer by increasing?notch1?expression and targeting tumor initiating cells\n",
      "Title T1: the fact inhibitor cbl0137 synergizes with cisplatin in small cell lung cancer by increasing?notch1?expression and targeting tumor initiating cells\n",
      "Drug T0: ['cbl1037', 'cisplatin']\n",
      "Drug T1: ['cbl0137']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: patient derived non small cell lung cancer xenograft mirrors complex tumor heterogeneity\n",
      "Title T1: patient derived non small cell lung cancer xenograft mirrors complex tumor heterogeneity\n",
      "Drug T0: ['atezolizumab', 'cisplatin']\n",
      "Drug T1: ['paclitaxel']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: differential antitumor activity of aflibercept and bevacizumab in patient derived xenograft models of colorectal cancer\n",
      "Title T1: differential antitumor activity of aflibercept and bevacizumab in patient derived xenograft models of colorectal cancer\n",
      "Drug T0: ['bevacizumab']\n",
      "Drug T1: ['bevacizumab']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 1.0000\n",
      "------------------------------------\n",
      "Title T0: discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes\n",
      "Title T1: discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes\n",
      "Drug T0: ['bevacizumab']\n",
      "Drug T1: ['topotecan']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: preclinical evaluation and phase ib study of prexasertib a chk1 inhibitor and samotolisib ly3023414 a dual pi3k mtor inhibitor\n",
      "Title T1: preclinical evaluation and phase ib study of prexasertib a chk1 inhibitor and samotolisib ly3023414 a dual pi3k mtor inhibitor\n",
      "Drug T0: ['prexasertib', 'samotolisib']\n",
      "Drug T1: ['ibrutinib']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: pharmacological targeting of androgen receptor elicits context specific effects in estrogen receptor positive breast cancer\n",
      "Title T1: pharmacological targeting of androgen receptor elicits context specific effects in estrogen receptor positive breast cancer\n",
      "Drug T0: ['fulvestrant']\n",
      "Drug T1: ['enzalutamide']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Title T1: acquired resistance to endocrine treatments is associated with tumor specific molecular changes in patient derived luminal breast cancer xenografts\n",
      "Drug T0: ['everolimus', 'fulvestrant', 'letrozole', 'ovariectomy', 'tamoxifen']\n",
      "Drug T1: ['everolimus']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.2000\n",
      "F1 (row): 0.3333\n",
      "------------------------------------\n",
      "Title T0: preclinical activity of her2 selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models\n",
      "Title T1: preclinical activity of her2 selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models\n",
      "Drug T0: ['docetaxel', 'trastuzumab', 'tucatinib']\n",
      "Drug T1: ['tucatinib']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.3333\n",
      "F1 (row): 0.5000\n",
      "------------------------------------\n",
      "Title T0: combination therapy with mdm2 and mek inhibitors is effective in patient derived models of lung adenocarcinoma with concurrent oncogenic drivers and mdm2 amplification\n",
      "Title T1: combination therapy with mdm2 and mek inhibitors is effective in patient derived models of lung adenocarcinoma with concurrent oncogenic drivers and mdm2 amplification\n",
      "Drug T0: ['milademetan', 'trametinib']\n",
      "Drug T1: ['trametinib', 'milademetan', 'selpercatinib']\n",
      "Precision (row): 0.6667\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 0.8000\n",
      "------------------------------------\n",
      "Title T0: palbociclib overcomes afatinib resistance in non small cell lung cancer\n",
      "Title T1: palbociclib overcomes afatinib resistance in non small cell lung cancer\n",
      "Drug T0: ['afatinib', 'palbociclib']\n",
      "Drug T1: ['palbociclib', 'letrozole', 'afatinib']\n",
      "Precision (row): 0.6667\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 0.8000\n",
      "------------------------------------\n",
      "Title T0: her2 exon 20 insertions in non small cell lung cancer are sensitive to the irreversible pan her receptor tyrosine kinase inhibitor pyrotinib\n",
      "Title T1: her2 exon 20 insertions in non small cell lung cancer are sensitive to the irreversible pan her receptor tyrosine kinase inhibitor pyrotinib\n",
      "Drug T0: ['afatinib']\n",
      "Drug T1: ['pyrotinib', 'afatinib', 'trastuzumabemtansine']\n",
      "Precision (row): 0.3333\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 0.5000\n",
      "------------------------------------\n",
      "Title T0: novel preclinical patient derived lung cancer models reveal inhibition of her3 and mtor signaling as therapeutic strategies for nrg1 fusion positive cancers\n",
      "Title T1: novel preclinical patient derived lung cancer models reveal inhibition of her3 and mtor signaling as therapeutic strategies for nrg1 fusion positive cancers\n",
      "Drug T0: ['afatinib']\n",
      "Drug T1: ['sirolimus', 'dnp53']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: rapid acquisition of alectinib resistance in alk positive lung cancer with high tumor mutation burden\n",
      "Title T1: rapid acquisition of alectinib resistance in alk positive lung cancer with high tumor mutation burden\n",
      "Drug T0: ['alectinib', 'crizotinib', 'erlotinib', 'lorlatinib']\n",
      "Drug T1: ['alectinib', 'lorlatinib']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.5000\n",
      "F1 (row): 0.6667\n",
      "------------------------------------\n",
      "Title T0: ono 7475 a novel axl inhibitor suppresses the adaptive resistance to initial egfr tki treatment in egfr mutated non small cell lung cancer\n",
      "Title T1: ono 7475 a novel axl inhibitor suppresses the adaptive resistance to initial egfr tki treatment in egfr mutated non small cell lung cancer\n",
      "Drug T0: ['osimertinib']\n",
      "Drug T1: ['tamnorzatinib']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: enhancing the therapeutic efficacy of gefitinib in human non small cell lung cancer through drug combination\n",
      "Title T1: enhancing the therapeutic efficacy of gefitinib in human non small cell lung cancer through drug combination\n",
      "Drug T0: ['dbdx', 'gefitinib']\n",
      "Drug T1: ['iodogen']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: xie bai san increases nsclc cells sensitivity to gefitinib by inhibiting beclin 1 mediated autophagosome formation\n",
      "Title T1: xie bai san increases nsclc cells sensitivity to gefitinib by inhibiting beclin 1 mediated autophagosome formation\n",
      "Drug T0: ['gefitinib', 'xbs']\n",
      "Drug T1: ['sirolimus', 'gefitinib']\n",
      "Precision (row): 0.5000\n",
      "Recall (row): 0.5000\n",
      "F1 (row): 0.5000\n",
      "------------------------------------\n",
      "Title T0: pharmacokinetic pharmacodynamic analysis of savolitinib plus osimertinib in an egfr mutation positive met amplified non small cell lung cancer model\n",
      "Title T1: pharmacokinetic pharmacodynamic analysis of savolitinib plus osimertinib in an egfr mutation positive met amplified non small cell lung cancer model\n",
      "Drug T0: ['osimertinib']\n",
      "Drug T1: ['osimertinib']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 1.0000\n",
      "------------------------------------\n",
      "Title T0: diverse resistance mechanisms to the third generation alk inhibitor lorlatinib in alk rearranged lung cancer\n",
      "Title T1: diverse resistance mechanisms to the third generation alk inhibitor lorlatinib in alk rearranged lung cancer\n",
      "Drug T0: ['lorlatinib']\n",
      "Drug T1: ['vistusertib']\n",
      "Precision (row): 0.0000\n",
      "Recall (row): 0.0000\n",
      "F1 (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: wee1 confers resistance to krasg12c?inhibitors in non small cell lung cancer\n",
      "Title T1: wee1 confers resistance to krasg12c inhibitors in non small cell lung cancer\n",
      "Drug T0: ['adavosertib', 'sotorasib']\n",
      "Drug T1: ['sotorasib', 'adavosertib', 'puromycin']\n",
      "Precision (row): 0.6667\n",
      "Recall (row): 1.0000\n",
      "F1 (row): 0.8000\n",
      "------------------------------------\n",
      "Title T0: antitumor efficacy of xpo1 inhibitor selinexor in?kras mutant lung adenocarcinoma patient derived xenografts\n",
      "Title T1: antitumor efficacy of xpo1 inhibitor selinexor in?kras mutant lung adenocarcinoma patient derived xenografts\n",
      "Drug T0: ['crizotinib', 'erlotinib', 'selinexor', 'trametinib']\n",
      "Drug T1: ['selinexor']\n",
      "Precision (row): 1.0000\n",
      "Recall (row): 0.2500\n",
      "F1 (row): 0.4000\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# 8Ô∏è‚É£ Recall Í≥ÑÏÇ∞: t0 Í∏∞Ï§Ä\n",
    "# ======================================\n",
    "def compute_recall(row):\n",
    "    set_pred = set(row[\"drug_t1_list\"])\n",
    "    set_true = set(row[\"drug_t0_list\"])\n",
    "    if len(set_true) == 0:\n",
    "        return 0\n",
    "    return len(set_pred & set_true) / len(set_true)\n",
    "\n",
    "matched_df[\"row_recall\"] = matched_df.apply(compute_recall, axis=1)\n",
    "recall_macro = matched_df[\"row_recall\"].mean()  # ÌñâÎ≥Ñ ÌèâÍ∑† Recall\n",
    "\n",
    "# Micro Recall (Ï†ÑÏ≤¥ Í∏∞Ï§Ä)\n",
    "all_true = matched_df[\"drug_t0_list\"].explode()\n",
    "all_pred = matched_df[\"drug_t1_list\"].explode()\n",
    "recall_micro = all_pred.isin(all_true).sum() / all_true.shape[0]\n",
    "\n",
    "# ======================================\n",
    "# 9Ô∏è‚É£ F1 Score Í≥ÑÏÇ∞\n",
    "# ======================================\n",
    "def compute_f1(p, r):\n",
    "    if (p + r) == 0:\n",
    "        return 0\n",
    "    return 2 * p * r / (p + r)\n",
    "\n",
    "matched_df[\"row_f1\"] = matched_df.apply(\n",
    "    lambda row: compute_f1(row[\"row_precision\"], row[\"row_recall\"]), axis=1\n",
    ")\n",
    "f1_macro = matched_df[\"row_f1\"].mean()\n",
    "\n",
    "# Micro F1 (Ï†ÑÏ≤¥ Í∏∞Ï§Ä)\n",
    "if (precision_micro + recall_micro) == 0:\n",
    "    f1_micro = 0\n",
    "else:\n",
    "    f1_micro = 2 * precision_micro * recall_micro / (precision_micro + recall_micro)\n",
    "\n",
    "# ======================================\n",
    "# 10Ô∏è‚É£ Í≤∞Í≥º Ï∂úÎ†•\n",
    "# ======================================\n",
    "print(\"\\n=== Drug Precision & Recall & F1 ===\")\n",
    "print(f\"üîπ Macro Precision (ÌñâÎ≥Ñ ÌèâÍ∑†): {precision_macro:.4f}\")\n",
    "print(f\"üîπ Micro Precision (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): {precision_micro:.4f}\")\n",
    "print(f\"üîπ Macro Recall (ÌñâÎ≥Ñ ÌèâÍ∑†): {recall_macro:.4f}\")\n",
    "print(f\"üîπ Micro Recall (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): {recall_micro:.4f}\")\n",
    "print(f\"üîπ Macro F1 (ÌñâÎ≥Ñ ÌèâÍ∑†): {f1_macro:.4f}\")\n",
    "print(f\"üîπ Micro F1 (Ï†ÑÏ≤¥ Í∏∞Ï§Ä): {f1_micro:.4f}\")\n",
    "\n",
    "# ÌñâÎ≥Ñ ÏÉÅÏÑ∏ Ï∂úÎ†• (ÏòµÏÖò)\n",
    "for idx, row in matched_df.iterrows():\n",
    "    print(\"------------------------------------\")\n",
    "    print(f\"Title T0: {row['title_t0']}\")\n",
    "    print(f\"Title T1: {row['title_t1']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0_list']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1_list']}\")\n",
    "    print(f\"Precision (row): {row['row_precision']:.4f}\")\n",
    "    print(f\"Recall (row): {row['row_recall']:.4f}\")\n",
    "    print(f\"F1 (row): {row['row_f1']:.4f}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e4f12be9",
   "metadata": {},
   "source": [
    "0.5Ïù¥Ìïò precision Í≤∞Í≥º ÌôïÏù∏ÌïòÍ∏∞"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "dcbaa057",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üîπ ÌñâÎ≥Ñ Precision <= 0.5Ïù∏ Í∞úÏàò: 17\n",
      "\n",
      "=== Low Precision Rows ===\n",
      "------------------------------------\n",
      "Title T0: phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation\n",
      "Title T1: phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation\n",
      "Drug T0: ['irinotecan', 'vemurafenib', 'cetuximab']\n",
      "Drug T1: ['irinotecanirinotecan']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: regorafenib suppresses epidermal growth factor receptor signaling modulated progression of colorectal cancer\n",
      "Title T1: regorafenib suppresses epidermal growth factor receptor signaling modulated progression of colorectal cancer\n",
      "Drug T0: ['regorafenib']\n",
      "Drug T1: ['regorafenib', 'erlotinib', '6bromo(2chlorophenyl)quinazoline2one']\n",
      "Precision (row): 0.3333\n",
      "------------------------------------\n",
      "Title T0: carbon nanotube capsules enhance the in vivo efficacy of cisplatin\n",
      "Title T1: carbon nanotube capsules enhance the in vivo efficacy of cisplatin\n",
      "Drug T0: ['cisplatin']\n",
      "Drug T1: ['bevacizumab']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: dual mtor kinase inhibitor mln0128 sensitizes hr+ her2+ breast cancer patient derived xenografts to trastuzumab or fulvestrant\n",
      "Title T1: dual mtor kinase inhibitor mln0128 sensitizes hr+ her2+ breast cancer patient derived xenografts to trastuzumab or fulvestrant\n",
      "Drug T0: ['trastuzumab']\n",
      "Drug T1: ['fulvestrant']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: 3 dimensional patient derived lung cancer assays reveal resistance to standards of care promoted by stromal cells but sensitivity to histone deacetylase inhibitors\n",
      "Title T1: 3 dimensional patient derived lung cancer assays reveal resistance to standards of care promoted by stromal cells but sensitivity to histone deacetylase inhibitors\n",
      "Drug T0: ['carboplatin', 'paclitaxel']\n",
      "Drug T1: ['quisinostat']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: preclinical antitumor efficacy of bay 1129980 a novel auristatin based anti c4.4a lypd3 antibody drug conjugate for the treatment of non small cell lung cancer\n",
      "Title T1: preclinical antitumor efficacy of bay 1129980 a novel auristatin based anti c4.4a lypd3 antibody drug conjugate for the treatment of non small cell lung cancer\n",
      "Drug T0: ['carboplatin', 'cisplatin', 'docetaxel']\n",
      "Drug T1: ['bay1129980']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: the fact inhibitor cbl0137 synergizes with cisplatin in small cell lung cancer by increasing?notch1?expression and targeting tumor initiating cells\n",
      "Title T1: the fact inhibitor cbl0137 synergizes with cisplatin in small cell lung cancer by increasing?notch1?expression and targeting tumor initiating cells\n",
      "Drug T0: ['cbl1037', 'cisplatin']\n",
      "Drug T1: ['cbl0137']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: patient derived non small cell lung cancer xenograft mirrors complex tumor heterogeneity\n",
      "Title T1: patient derived non small cell lung cancer xenograft mirrors complex tumor heterogeneity\n",
      "Drug T0: ['atezolizumab', 'cisplatin']\n",
      "Drug T1: ['paclitaxel']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes\n",
      "Title T1: discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes\n",
      "Drug T0: ['bevacizumab']\n",
      "Drug T1: ['topotecan']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: preclinical evaluation and phase ib study of prexasertib a chk1 inhibitor and samotolisib ly3023414 a dual pi3k mtor inhibitor\n",
      "Title T1: preclinical evaluation and phase ib study of prexasertib a chk1 inhibitor and samotolisib ly3023414 a dual pi3k mtor inhibitor\n",
      "Drug T0: ['prexasertib', 'samotolisib']\n",
      "Drug T1: ['ibrutinib']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: pharmacological targeting of androgen receptor elicits context specific effects in estrogen receptor positive breast cancer\n",
      "Title T1: pharmacological targeting of androgen receptor elicits context specific effects in estrogen receptor positive breast cancer\n",
      "Drug T0: ['fulvestrant']\n",
      "Drug T1: ['enzalutamide']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: her2 exon 20 insertions in non small cell lung cancer are sensitive to the irreversible pan her receptor tyrosine kinase inhibitor pyrotinib\n",
      "Title T1: her2 exon 20 insertions in non small cell lung cancer are sensitive to the irreversible pan her receptor tyrosine kinase inhibitor pyrotinib\n",
      "Drug T0: ['afatinib']\n",
      "Drug T1: ['pyrotinib', 'afatinib', 'trastuzumabemtansine']\n",
      "Precision (row): 0.3333\n",
      "------------------------------------\n",
      "Title T0: novel preclinical patient derived lung cancer models reveal inhibition of her3 and mtor signaling as therapeutic strategies for nrg1 fusion positive cancers\n",
      "Title T1: novel preclinical patient derived lung cancer models reveal inhibition of her3 and mtor signaling as therapeutic strategies for nrg1 fusion positive cancers\n",
      "Drug T0: ['afatinib']\n",
      "Drug T1: ['sirolimus', 'dnp53']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: ono 7475 a novel axl inhibitor suppresses the adaptive resistance to initial egfr tki treatment in egfr mutated non small cell lung cancer\n",
      "Title T1: ono 7475 a novel axl inhibitor suppresses the adaptive resistance to initial egfr tki treatment in egfr mutated non small cell lung cancer\n",
      "Drug T0: ['osimertinib']\n",
      "Drug T1: ['tamnorzatinib']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: enhancing the therapeutic efficacy of gefitinib in human non small cell lung cancer through drug combination\n",
      "Title T1: enhancing the therapeutic efficacy of gefitinib in human non small cell lung cancer through drug combination\n",
      "Drug T0: ['dbdx', 'gefitinib']\n",
      "Drug T1: ['iodogen']\n",
      "Precision (row): 0.0000\n",
      "------------------------------------\n",
      "Title T0: xie bai san increases nsclc cells sensitivity to gefitinib by inhibiting beclin 1 mediated autophagosome formation\n",
      "Title T1: xie bai san increases nsclc cells sensitivity to gefitinib by inhibiting beclin 1 mediated autophagosome formation\n",
      "Drug T0: ['gefitinib', 'xbs']\n",
      "Drug T1: ['sirolimus', 'gefitinib']\n",
      "Precision (row): 0.5000\n",
      "------------------------------------\n",
      "Title T0: diverse resistance mechanisms to the third generation alk inhibitor lorlatinib in alk rearranged lung cancer\n",
      "Title T1: diverse resistance mechanisms to the third generation alk inhibitor lorlatinib in alk rearranged lung cancer\n",
      "Drug T0: ['lorlatinib']\n",
      "Drug T1: ['vistusertib']\n",
      "Precision (row): 0.0000\n"
     ]
    }
   ],
   "source": [
    "# Precision 0.5 Ïù¥Ìïò ÌïÑÌÑ∞ÎßÅ\n",
    "low_precision_df = matched_df[matched_df[\"row_precision\"] <= 0.5]\n",
    "\n",
    "print(f\"üîπ ÌñâÎ≥Ñ Precision <= 0.5Ïù∏ Í∞úÏàò: {len(low_precision_df)}\")\n",
    "print(\"\\n=== Low Precision Rows ===\")\n",
    "for idx, row in low_precision_df.iterrows():\n",
    "    print(\"------------------------------------\")\n",
    "    print(f\"Title T0: {row['title_t0']}\")\n",
    "    print(f\"Title T1: {row['title_t1']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0_list']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1_list']}\")\n",
    "    print(f\"Precision (row): {row['row_precision']:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "80e53238",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
